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Abstract 134 
The present publication surveys several applications of in silico (i.e., computational) toxicology 135 
approaches across different industries and institutions. It highlights the need to develop standardized 136 
protocols when conducting toxicity-related predictions. This contribution articulates the information 137 
needed for protocols to support in silico predictions for major toxicological endpoints of concern (e.g., 138 
genetic toxicity, carcinogenicity, acute toxicity, reproductive toxicity, developmental toxicity) across 139 
several industries and regulatory bodies. Such novel in silico toxicology (IST) protocols, when fully 140 
developed and implemented, will ensure in silico toxicological assessments are performed and 141 
evaluated in a consistent, reproducible, and well-documented manner across industries and regulatory 142 
bodies to support wider uptake and acceptance of the approaches. The development of IST protocols is 143 
an initiative developed through a collaboration among an international consortium to reflect the state-144 
of-the-art in in silico toxicology for hazard identification and characterization. A general outline for 145 
describing the development of such protocols is included and it is based on in silico predictions and/or 146 
available experimental data for a defined series of relevant toxicological effects or mechanisms. The 147 
publication presents a novel approach for determining the reliability of in silico predictions alongside 148 
experimental data. In addition, we discuss how to determine the level of confidence in the assessment 149 
based on the relevance and reliability of the information. 150 
  151 
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Graphical abstract 152 
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Keywords: In silico, in silico toxicology, computational toxicology, predictive toxicology, QSAR, expert 155 
alert, expert review. 156 
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 General outline of in silico toxicology protocols is described 159 
 A reliability score for predictions alongside experimental data is discussed 160 
 A checklist for performing an expert review of the in silico results is outlined 161 
 A hazard assessment framework is proposed that includes in silico results 162 
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1. Introduction 168 
In silico toxicology (IST) methods are computational approaches that analyze, simulate, visualize, or 169 
predict the toxicity of chemicals. IST encompasses all methodologies for analyzing chemical and 170 
biological properties generally based upon a chemical structure that represents either an actual or a 171 
proposed (i.e., virtual) chemical. Today, in silico approaches are often used in combination with other 172 
toxicity tests; however, the approaches are starting to be used to generate toxicity assessments 173 
information with less need to perform any in vitro or in vivo studies depending on the decision context. 174 
IST uses models which can be encoded within software tools to predict the potential toxicity of a 175 
chemical and in some situations to quantitatively predict the toxic dose or potency. These models are 176 
based on experimental data, structure-activity relationships, and scientific knowledge (such as structural 177 
alerts reported in the literature).  178 
There are a number of different situations where in silico methods serve an important role in the hazard 179 
assessment of existing chemicals or new substances under development that would benefit from the 180 
development of in silico toxicology protocols. These include:  181 
 emergency situations where rapid understanding of potential toxicological consequences from 182 
exposure is needed in the absence of existing toxicological testing data;  183 
 cases where there is only a limited supply of a test material available; 184 
 scenarios where there are challenges to conduct laboratory studies;  185 
 instances where synthesis of a complex test material is not feasible; and 186 
 situations where a less time-consuming and less expensive high-throughput approach than an 187 
experimental test is needed. 188 
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IST methods are one approach to generating additional information for complementing and ultimately 189 
enhancing the reliability or supporting a risk assessment, including an understanding of the structural 190 
and/or mechanistic basis that may contribute ideas for the rational design of new chemicals, 191 
development of a testing strategy or an overall weight-of-evidence evaluation. IST inherently supports 192 
the principle of the 3Rs (replacement, refinement and reduction) relating to the use of animals in 193 
research (Russell and Burch, 1959; Ford 2016). Table 1 outlines fifteen specific uses of IST to illustrate 194 
the diversity of applications that currently can benefit from in silico methods. Stanton and Kruszewski 195 
(2016) recently quantified the benefits of using in silico and read-across methods where they 196 
determined that the approach used across two voluntary high-production-volume (HPV) chemical 197 
programs for 261 chemicals obviated the use of 100,000 – 150,000 test animals and saved 50,000,000 198 
US$ to 70,000,000 US$.  199 
The increased interest and acceptance of in silico methods for regulatory data submission and chemicals 200 
evaluation is driving the adoption of its use for regulatory purposes. Several guidance documents have 201 
been drafted to improve standardization, harmonization, and uptake of in silico methods by regulatory 202 
authorities including  the International Council for Harmonization (ICH) M7 guideline (assessment and 203 
control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk) 204 
(ICH M7, 2017(R1)), the EuropeaŶ UŶioŶ’s RegistratioŶ, EǀaluatioŶ, Authorization, and restriction of 205 
Chemicals (REACH) regulation (EU 2006; ECHA 2008; ECHA 2015), European Food Safety Authority 206 
(EFSA) residue guidance (EFSA 2016), CaŶada’s chemicals management plan assessments for new and 207 
existing substances under the Canadian Environmental Protection Act (CEPA) (Canada 2016), and the 208 
Toxic Substances Control Act (TSCA) (TSCA 2016). A number of national and international initiatives have 209 
focused on developing specific documents supporting the use of in silico tools. The OECD has published 210 
a series of (Quantitative) Structure-Activity Relationship (Q)SAR validation principles that are discussed 211 
in detail in Section 2.3.2. (OECD 2004, OECD 2007) Other initiatives include the North American Free 212 
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Trade Agreement pesticides Quantitative Structure-Activity Relationship (QSAR) guidance (NAFTA 2012), 213 
considerations on the use of in silico approaches for assessing cosmetics ingredients (Amaral et al., 214 
2014), European Food Safety Agency report (EFSA 2014), European Chemicals Agency REACH supporting 215 
documentation (ECHA 2008; ECHA 2016, 2017), Organization for Economic Co-operation and 216 
Development (OECD) documentation (OECD 2007; OECD 2014; OECD 2015), and the ICH M7 guideline 217 
for prediction of mutagenicity (ICH M7, 2017(R1)), along with complementary peer reviewed 218 
publications outlining the process for implementation of such computational assessments (e.g., Amberg 219 
et al., 2016; Barber et al., 2015; Powley et al., 2015; Schilter et al., 2014). Certain projects have provided 220 
substantial guidance on the documentation of the models and prediction results (JRC 2014; Patlewicz et 221 
al., 2016) as well as principles and workflows to support safety assessments (Bassan and Worth, 2008; 222 
ECHA 2015; Worth et al., 2014; Berggren et al., 2017; Amaral et al., 2017). 223 
These prior initiatives provide a robust foundation for the current project to establish the IST protocols 224 
described here; however, several issues have hindered the general acceptance and use of in silico 225 
methods on a larger scale. In particular, there remains a lack of generally accepted procedures for 226 
performing in silico assessments for the toxicological endpoints. The lack of such procedures or 227 
protocols has led to inconsistency in the application and use of in silico tools across different 228 
organizations, industries, and regulatory agencies (e.g., searching databases, applying predictive models 229 
and alerts, performing an expert review/assessment, documenting and communicating the results and 230 
associated uncertainties). The use of traditional experimental evidence coupled with in silico 231 
information to support hazard identification and risk assessment also varies both across, and often 232 
within, organizations. Although not always, such ad hoc approaches may be time-consuming and the 233 
results poorly accepted. Standardization of protocols will enhance the acceptability of the methods and 234 
their results by end users. Additionally, there are misconceptions about when in silico predictions are 235 
appropriate to use as well as a lack of defined consensus processes for interpreting the result(s) of such 236 
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predictions (Bower et al., 2017; SCCS 2016). Some scientists view in silico methods as a ͞ďlaĐk ďoǆ͟ that 237 
inhibits their ability to critically assess the predictions and their reliability. (Alves et al., 2016) Others lack 238 
expertise to interpret the results of in silico predictions, and some have an unrealistic expectation that 239 
an in silico prediction can always provide an unerring definitive assessment.  240 
Standardization of in silico tool use and interpretation of results would greatly reduce the burden on 241 
both industry and regulators to provide confidence in or justification for the use of these approaches. 242 
The objective of developing IST protocols is to define in silico assessment principles so the results can 243 
be generated, recorded, communicated, archived and then evaluated in a uniform, consistent and 244 
reproducible manner. Incorporating these principles routinely into the use of in silico methods will 245 
support a more transparent analysis of the results and serves to ŵitigate ͞ďlaĐk ďoǆ͟ ĐoŶĐerŶs1. This 246 
approach is similar to guideline studies that provide a framework for the proper conduct of 247 
toxicological studies and assurance in the validity of the results (such as OECD Guidelines for the 248 
Testing of Chemicals) (OECD 2017). The development of these protocols is driven by consensus 249 
amongst leading scientists representing industry, private sector and governmental agencies. 250 
Consequently, this project provides an important step towards a quality-driven science for IST or good 251 
in silico practice . 252 
Herein, we provide a framework to develop a series of procedures for performing an in silico assessment 253 
to foster greater acceptance. These IST protocols are being created for a number of toxicological 254 
endpoints (e.g., genetic toxicity, carcinogenicity, acute toxicity, reproductive toxicity, developmental 255 
toxicity) as well as other related properties (e.g., biodegradation and bioaccumulation) that could 256 
impact the chemical hazard classification. Throughout this publication, these toxicological and related 257 
                                                 
1It should be noted that black box models may be acceptable in certain situations, such as compound filtering and 
virtual screening, as long as they show acceptable performance in validation studies; however, for most 
applications the acceptance of this class of models is low. 
In silico toxicology protocol (17 November 2017) Page 15 
 
endpoiŶts are referred to as ͞ŵajor eŶdpoiŶts͟ aŶd the protoĐols are referred to as I“T protoĐols. These 258 
protocols will support the assessment of hazards and in some cases the prediction of quantitative 259 
values, such as a No Observed Adverse Effect Levels (NOAELs); however, these protocols do not define 260 
how a risk assessment will be performed. This publication outlines the components of an IST protocol, 261 
including schematics to describe how a prediction could be performed, approaches to assess the 262 
reliability and confidence of the results, and items that may be considered as part of an expert review. 263 
This publication also outlines the process for creating the IST protocols through an international 264 
consortium comprising representatives across regulatory agencies, government research agencies, 265 
different industrial sectors, academia and other stakeholders. Specific endpoint-dependent 266 
considerations will be described in future separate publications and IST protocols (developed as a result 267 
of this process) will also be published for widespread use and for incorporation into different technology 268 
platforms. 269 
2. In silico toxicology protocols 270 
2.1 Overview 271 
Each IST protocol describes the prediction process in a consistent, transparent, and well-documented 272 
manner. This includes recommendations on how to:  273 
1) plan the in silico analyses including identifying what toxicological effects or mechanisms to 274 
predict (Section 2.2), what in silico methodologies to use (Section 2.3.1), and other selection 275 
criteria for the in silico methods (Section 2.3.2),  276 
2) conduct the appropriate individual software predictions (Section 2.3.3) and further database 277 
searches (Section 2.5),  278 
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3) perform and document the in silico analysis (Sections 2.6 and 2.7) including expert review 279 
(Section 2.4), and  280 
4) report and share the information and assessment results, including information about 281 
uncertainties (Section 2.9).  282 
Section 2.8 provides a template for the individual IST protocols for major toxicological endpoints. IST 283 
protocols could be applicable for use with several in silico programs, including different in silico models 284 
and databases. 285 
2.2 Toxicological effects and mechanisms 286 
In an experimental approach, hazard is evaluated based on specific observations (toxicological effects) 287 
during toxicity studies. Often, toxicity of a chemical involves a biological event: a non-specific or specific 288 
interaction with a vital biological structure, which causes sequential perturbation of a physiological 289 
pathway at a cellular, tissue, organ and/or system level, leading to a toxicological effect observed at the 290 
organism level. Experiments evaluating the potential of a chemical to cause such a biological event (e.g., 291 
in vitro analysis of specific interaction with a cellular receptor or inhibition of an enzyme or non-specific 292 
cytotoxicity), may support hazard assessment and provide information about the mechanism of toxicity. 293 
Such an approach is utilized in the Adverse Outcome Pathway (AOP), where identification of a molecular 294 
initiating event supports assessment of the related adverse outcome at the organism level (Bell et al., 295 
2016; OECD 2016a; OECD 2016b).  A computational approach to hazard assessment may address the 296 
two complementary levels of hazard identification in a similar way (i.e., predicting the resulting 297 
manifestation (effect) or the molecular perturbation (mechanism) that led to the toxicological effect).  298 
Each IST protocol defines a series of known toxicological effects and mechanisms relevant to the 299 
assessment of the major toxicological endpoint. For example, in the reproductive toxicity IST protocol, 300 
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the list of toxicological effects/mechanisms may include reduced sperm count, androgen signaling 301 
disruption in vitro, and so on. Within each IST protocol, these effects/mechanisms may be species 302 
and/or route of administration specific. 303 
Figure 1 outlines a general approach to performing an in silico assessment. For each toxicological 304 
effect/mechanism, relevant information (as defined in the IST protocol) is collected, including any 305 
available experimental data as well as in silico predictions. The experimental data and/or in silico results 306 
are then analyzed and an overall assessment of the toxicological effect or mechanism is generated 307 
alongside a reliability score (defined in Section 2.6.2) that reflects the quality of the results. The 308 
assessment results and reliability scores for a range of relevant toxicological effects/mechanisms are 309 
then used to support a hazard assessment within the hazard assessment framework. 310 
2.3 In silico predictions 311 
2.3.1 In silico methodologies 312 
Several organizations develop and make available computer software packages for predicting toxicity or 313 
physicochemical properties of query chemical(s). These systems generally contain one or more models, 314 
where each model predicts the compound’s putatiǀe toxicological effect or mechanism of action. For 315 
example, a model may predict the results for bacterial gene mutation using data generated from the 316 
bacterial reverse mutation test or Ames test. These models may be revised over time as more data 317 
become available, structure-activity relationships are better characterized, and any data set used is 318 
updated. Each new or updated model is given a different version number because the results from 319 
different model versions may vary and it is important to track the source of the results. (Amberg et al., 320 
2016) 321 
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All IST protocols will identify the toxicological effects or mechanisms to be predicted as discussed in 322 
Section 2.2. These predictions may be dichotomous (e.g., predict mutagenic or non-mutagenic 323 
compounds), quantal (e.g., Globally Harmonized System [GHS] Classification and Labeling2 scheme) or 324 
quantitative/continuous (e.g., prediction of median toxic dose [TD50] values). The specific IST protocols 325 
will detail the type of prediction(s) ideally generated. 326 
The major in silico prediction methodologies include the following: 327 
 Statistical-based (or QSAR). This methodology uses a mathematical model that was derived 328 
from a training set of example chemicals. The training set includes the chemicals that were 329 
found to be positive and negative in a given toxicological study (e.g., the bacterial reverse 330 
mutation assay) or to induce a continuous response (e.g., NOAEL in teratogenicity) that the 331 
model will predict. As part of the process to generate the model, physicochemical property-332 
based descriptors (e.g., molecular weight, octanol water partition coefficient [log P]), electronic 333 
and topological descriptors (e.g., quantum mechanics calculations), or chemical structure-based 334 
descriptors (e.g., the presence or absence of different functional groups) are generated and 335 
used to describe the training set compounds. The model encodes the relationship between 336 
these descriptors and the (toxicological) response. After the model is built and validated (OECD 337 
2007; Myatt et al., 2016), it can be used to make a prediction. The (physico)chemical descriptors 338 
incorporated into the model are then generated for the test compound and are used by the 339 
model to generate a prediction. This prediction is only accepted when the test compound is 340 
sufficiently similar to the training set compounds (i.e., it is considered within the applicability 341 
domain of the QSAR model, often considering the significance of descriptors). (Netzeva et al., 342 
2005; Carrió et al., 2014; Patlewicz et al., 2016) This applicability domain analysis may be 343 
                                                 
2 A chemical is assigned to a category (e.g., 1, 2, 3, 4, or 5) based on distinct ranges of quantitative values (e.g., LD50). Examples 
of such ranges include LD50 <5mg/kg (i.e., category 1) or 50-300mg/kg (i.e., category 3). 
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performed automatically by some software to determine whether the training set compounds 344 
share similar chemical and/or biological properties with the test chemical. 345 
 Expert rule-based (or expert/structural alerts). This methodology uses structural rules or alerts 346 
to make predictions for specific toxicological effects or mechanisms of toxicity. These rules are 347 
derived from the literature or from an analysis of data sets generated by scientists. Structural 348 
alerts are defined as molecular substructures that can activate the toxicological effect or 349 
mechanism. The rules may also encode situations where the alert is deactivated. Expert rule-350 
based models often include a description of the toxic mechanism and examples from the 351 
literature or other reference sources to justify the structural alert. A positive prediction is 352 
generally made when a structural alert is present (without deactivating structural features or 353 
properties) in the test compound. When no alerts are triggered for a test chemical, a negative 354 
prediction may be generated for well investigated endpoints; however, additional analysis is 355 
generally required to make this assessment as discussed further in Section 2.4.3. 356 
 Read-across: Read-across uses data on one or more analogs (the ͞source͟) to make a prediction 357 
about a query compound or compounds ;the ͞target͟Ϳ. Source compounds are identified that 358 
have a structurally or toxicologically meaningful relationship to the target compound, often 359 
underpinned by an understanding of a plausible biological mechanism shared between the 360 
source and target compounds. The toxicological experimental data from these source 361 
ĐoŵpouŶds ĐaŶ theŶ ďe used to ͞read-aĐross͟ to the specific target compound(s). Read-across is 362 
an intellectually-derived endpoint-specific method that provides justification for why a chemical 363 
is similar to another chemical (with respect to chemical reactivity, toxicokinetics, 364 
mechanism/mode of action, structure, physicochemical properties, and metabolic profile). (Wu 365 
et al., 2010; ECETOC 2012; Patlewicz et al., 2013a; Patlewicz et al., 2013b; OECD 2014; Blackburn 366 
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and Stuard, 2014; Patlewicz (2014); Patlewicz et al., 2015; Schultz et al., 2015; Ball et al., 2016; 367 
ECHA 2017b) 368 
 Other approaches: In certain cases, other in silico methodologies may be appropriate. Examples 369 
include the use of molecular dynamics (e.g., simulating interactions of a query chemical with a 370 
metabolic enzyme) and receptor binding as an indication of a possible Molecular Initiating Event 371 
(e.g., estrogen receptor-ligand docking).  372 
Each IST protocol will include an assessment of key computational aspects and specific issues to 373 
consider. For example, when performing read-across, issues such as the data quality of the source 374 
compound(s), how to perform an assessment of non-reactive chemical features and selection of 375 
grouping approaches used to form categories will be discussed to ensure source compound(s) are 376 
sufficiently similar, both chemically and biologically, for the endpoint being considered. 377 
Each methodology has its strengths and weaknesses, which often depend on the type of toxicological 378 
effect or mechanism being predicted. This will be discussed in the individual IST protocols. In addition, 379 
there may be cases of unique or novel compounds for which it is not possible to make a prediction or for 380 
which confidence in the predictions is so low as to render it meaningless or unhelpful. 381 
2.3.2 In silico methods selection criteria 382 
In silico methods selection may include the following five considerations: 383 
1. Relevant toxicological effects or mechanisms. As discussed in Section 2.2, each IST protocol will 384 
define a series of toxicological effects or mechanisms relevant to a specific endpoint and 385 
appropriate in silico models need to be selected that predict these specific effects or 386 
mechanisms. 387 
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2. Model validity. Best practices for validation of (Q)SAR in silico models have been documented in 388 
a number of publications (Cherkasov et al.; 2014, Raies and Bajic, 2016; Myatt et al., 2016), and 389 
models built using these best practices may be preferred. The OECD has published a series of 390 
validation principles for in silico models (OECD 2004; OECD 2007) and valid statistical-based or 391 
expert rule-based in silico methods. Such (Q)SAR methods have: 1) a defined endpoint; 2) an 392 
unambiguous algorithm; 3) a defined domain of applicability; 4) appropriate measures of 393 
goodness-of-fit, robustness and predictivity; and 5) a mechanistic interpretation, if possible. Any 394 
in silico model must iŶĐlude doĐuŵeŶtatioŶ that supports aŶ assessŵeŶt of the ŵodel’s 395 
scientific validity, including the toxicological effect or mechanism being predicted, version 396 
number, type of methodology, training set size and content, as well as any predictive 397 
performance information. Validation performance is documented in report formats such as the 398 
QSAR Model Reporting Format (QMRF) (JRC 2014). The level of adherence to the OECD 399 
principles and the performance statistics need to be appropriate for the purpose of the 400 
assessment.  401 
3. Chemical space. Often, in silico models will only make predictions for specific classes of 402 
chemicals, the so Đalled ͞appliĐaďilitǇ doŵaiŶ͟. The ĐhoseŶ in silico model(s) may report the 403 
applicability domain assessment to demonstrate its proficiency for this class of compounds. Vice 404 
versa, only models are ideally chosen where the query compound is in the applicability domain. 405 
(Netzeva et a l., 2005; Carrió et al., 2014; Patlewicz et al., 2016) 406 
4. Model combinations. Complementary or independent in silico models may be selected, as 407 
concurring results increase the reliability of the prediction (as discussed in Section 2.6.2).  408 
5. Supporting an expert review. For QSAR models, tools to help the expert review (see Section 2.4) 409 
include the ability to allow examination of the descriptors and weightings used in the model, 410 
underlying training set data, and how the applicability domain assessment was defined. For 411 
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expert rule-based systems, this could include how the alert was defined (including any factors 412 
that activate or deactivate the alert), any mechanistic understanding associated with the alert, 413 
citations, and any relevant known examples of alerting chemicals. 414 
Read across may be used when there are experimental data from high quality databases for one or more 415 
substances which are similar enough to the target chemical of interest. The Read-Across Assessment 416 
Framework (RAAF), or similar published and established frameworks, may be used to document the 417 
read-across assessment and to support its scientific plausibility (ECHA 2017b; Patlewicz et al., 2013b; 418 
Blackburn & Stuard 2014; Schultz et al., 2015; Patlewicz et al., 2015). The OECD has also produced 419 
guidance on the process of grouping chemicals and other considerations as part of a read-across 420 
assessment (OECD 2014), and ECHA has generated guidelines on the process of performing a valid read-421 
across assessment (ECHA 2008).  422 
2.3.3 Running the in silico models 423 
All in silico systems require an electronic representation of the chemical structure and any errors in this 424 
representation will result in invalid predictions. Therefore, it is important to ensure that the chemical 425 
structure is properly curated and eŶtered folloǁiŶg ĐoŶǀeŶtioŶs set out ďǇ the ŵodel’s deǀeloper, 426 
including appropriate representations for tautomers, aromaticity, salt forms, stereochemistry, charges, 427 
and specific functional groups (e.g., nitro or carboxylic acid groups). It is possible that different formats 428 
(i.e., SMILES vs. MOL files) may be processed differently. It is also important to verify that the software 429 
correctly interprets the structural representation during processing, particularly for complex molecules. 430 
For some types of chemicals, in silico models may not be applicable due to the structural representation 431 
or the unsuitability of the experiment assay for the specific chemical class. Examples include non-432 
discrete chemical substances, UVCBs (unknown/variable composition, complex reaction products and 433 
In silico toxicology protocol (17 November 2017) Page 23 
 
biologicals), metals, inorganics, polymers, mixtures, organometallics and nano-materials. (Mansouri et 434 
al., 2016)  435 
Some models, such as statistical-based models, allow for prediction settings to be adjusted or turned off 436 
(e.g., they report ͞positiǀe͟ when a value is greater than a predetermined threshold). The settings are 437 
ideally selected in a way that does Ŷot Đoŵproŵise the ŵodel’s ǀaliditǇ (such as changing the validation 438 
statistics of the model) and appropriately reported. 439 
A thorough documentation of all selected models and computer software packages including, version 440 
numbers, and any parameters set, is needed as part of the materials and methods in sufficient detail to 441 
assess and potentially repeat the analysis (discussed in Section 2.9). In addition, the results need to be 442 
presented in enough detail to fully understand how they were generated and to critically assess the 443 
findings. 444 
2.4 In silico expert review 445 
2.4.1 Overview 446 
As with in vitro or in vivo study data, in silico predictions may be critically assessed and an expert review 447 
of the output is often prudent (Dobo et al., 2012; Sutter et al., 2013). Frameworks for conducting an 448 
expert review ensure that it is performed in a consistent and transparent manner. Examples of such a 449 
review framework include the Office of Health Assessment and Translation (OHAT) systematic review 450 
and evidence integration (Rooney et al., 2014), weight-of-evidence assessments (ECHA 2017a), and 451 
Integrated Approaches to Testing and Assessment (IATA) (OECD 2016a; OECD 2016b).  452 
The purpose of an in silico expert review is to evaluate the reliability of the prediction. The outcome of 453 
the review provides information to include in the assessment of the toxicological effect or mechanism. 454 
As part of this review, the expert might agree with, or refute, individual in silico predictions. In addition, 455 
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these reviews might support cases when a chemical is out of the applicability domain of the model, 456 
support the use of an equivocal prediction (i.e., there is evidence both for and against the supposition), 457 
or support cases where multiple predictions do not agree. A checklist of items to consider and report 458 
will help to ensure such reviews are performed in a consistent manner (as illustrated in Tables 2 and 3). 459 
This review may include knowledge from proprietary information available within an organization from 460 
the testing of related chemicals. 461 
When an expert review assesses multiple predictions from different in silico systems, it is important to 462 
justify how they complement each other with regard to the training set (i.e., the use of relevant 463 
guideline studies plus relevant chemical classes), methodology (e.g., expert rule-based vs. statistical-464 
based vs. read-across), or QSAR descriptor sets. 465 
It is essential to document the reasoning and decisions of the expert review steps so they can be 466 
retraced at any time, including the information used as the basis for the review. 467 
2.4.2 Expert review of statistical models 468 
An expert review of a statistical-based model involves a critical assessment of how the model generated 469 
the prediction. This includes examining the weightings of the model descriptors (e.g., structural features 470 
or physicochemical properties related to toxicity), underlying data, chemical space of the training set of 471 
the model, and the experimental results for analog compounds and model performance for these 472 
analogs (e.g., nearest-neighbor list of compounds) (Amberg et al., 2016). This may also incorporate an 473 
understanding of the mechanism of toxicity or knowledge of factors that activate or deactivate the 474 
toxicity. The items described in Table 2 provide a checklist of elements to consider as part of any QSAR 475 
expert review to ensure such a review is as objective as possible, transparent and based on a consistent 476 
set of considerations. An expert review may increase the reliability of statistical model results based on 477 
one or more elements defined in Table 2. 478 
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Individual IST protocols will outline specific points to consider when performing an expert review, such 479 
as how the similarity of analogs could be assessed. 480 
2.4.3 Expert review of expert rule-based (structural) alert systems 481 
An expert review of the results from an expert rule-based alert system may involve inspection of the 482 
underlying information as well as external knowledge. Special emphasis needs to be placed on the 483 
assessment of chemicals where no alerts are identified in the expert alert system. When no alert is fired 484 
(i.e., it is not predicted active), it is often not reported if the prediction is negative, equivocal, or out of 485 
the applicability domain of the model and often no prediction is generated. An expert review may 486 
increase the reliability of the results based on one or more elements defined in Table 3. 487 
2.4.4 Read-across expert review 488 
Read-across contains an expert assessment by its nature: it requires expert judgment of the analogs, 489 
their data and extrapolation to the query chemical. For example, read-across assessments performed 490 
and documented according to the RAAF (i.e., following the detailed RAAF Assessment Elements), or 491 
similar frameworks, as discussed earlier, incorporate an expert review as part of the assessment. This 492 
type of assessment includes a strong justification for biological plausibility of any analogs selected 493 
(including an assessment of the structural differences and similarities to the target structure, and an 494 
analysis of potential metabolism). It also includes an expert assessment when a read-across prediction 495 
concludes there is an absence of effects. In addition, an assessment of supporting evidence (including 496 
the reliability of the source data), any weight-of-evidence considerations, and an assessment of any 497 
possible bias in the selection of source chemicals is required.  498 
2.5 Assessment of available experimental data 499 
Experimental data may have been previously generated and reported for a chemical being assessed, for 500 
example, in the literature or through a public or proprietary database. To support the identification of 501 
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experimental data, each IST protocol will identify a series of relevant study types and specific result(s) 502 
corresponding to the identified toxicological effects or mechanisms, as discussed in Section 2.2. To 503 
illustrate, in the assessment of the toxicological effect/mechanism bacterial gene mutation (part of the 504 
genetic toxicity IST protocol), the overall mutagenic or non-mutagenic results from a bacterial reverse 505 
mutation assay may be used. A more complex example is in the assessment of the toxicological 506 
effect/mechanism of sperm morphology (part of the reproductive IST protocol). Here, specific results 507 
from potentially different study types, such as one- or two- generation reproductive studies, repeated 508 
dose toxicity studies or segment I (fertility) studies, and possibly also from different species (rat, mouse, 509 
rabbit) will be applicable. 510 
The selection of experimental study types need focus on those that have general value based on 511 
scientific justification. This includes study types that have widespread use in risk assessments, regulatory 512 
acceptance and that follow internationally recognized test guidelines. In addition, other types of data 513 
may be considered relevant on a case-by-case basis. Numerous guidance documents discuss acceptable 514 
studies, their relevancy, and their use in hazard identification, hazard characterization and risk 515 
assessment. These include guidance documents from the ICH (ICH 2017), OECD (OECD 2017), European 516 
Food Safety Authority (EFSA) (EFSA 2017a), Scientific Committee on Consumer Safety (SCCS) (SCCS 517 
2017), REACH /ECHA (ECHA 2008; ECHA 2015), United States Environmental Protection Agency (EPA) 518 
Office of Chemical Safety and Pollution Prevention (OCSPP 2015), and National Institute of 519 
Environmental Health Sciences (NIEHS) (NIEHS 2017) guidance documents. Such guidance documents 520 
provide a useful basis for test considerations but may not always be harmonized across legislation, 521 
industrial sector or geographical regions, as requirements may differ across guidance documents.  522 
The IST protocols will discuss how to assess and document the experimental data and uncertainties to 523 
ensure the proper justification of the experimental results’ reliability, including defining what specific 524 
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elements or fields are important to document. With older studies pre-dating existing guidelines, it will 525 
often still be possible to perform an expert review to determine the adequacy of the data, but it will be 526 
important to document specifically why the study results were considered acceptable or dismissed as 527 
unacceptable. The IST protocols will also provide recommendations on how to select a result when 528 
multiple studies (with potentially conflicting results) for the same effect or mechanism are reported. 529 
Klimisch scores are a widely used approach adopted to support an assessment of experimental data 530 
reliability (Table 4; Klimisch et al., 1997). The Klimisch score (1 to 4) is based on factors including 531 
whether the test was compliant with the OECD principles of Good Laboratory Practices (GLP) or Good In 532 
Vitro Methods Practices (GIVIMP) standards (OECD 2016c), whether the data were generated using 533 
accepted test guidelines, whether the data are available for independent inspection, and the quality of 534 
the report. ECHA uses this score, for example, as part of its data submission process (ECHA 2011), and 535 
there are tools to support the assignment of Klimisch scores (ECVAM 2017; Schneider et al., 2009). 536 
Another approach to the assessment of the reliability of the experimental data is the Science in Risk 537 
Assessment and Policy (SciRAP) application, a web-based reporting and evaluation resource created to 538 
help understand how academic toxicity-related studies can be used as part of any regulatory assessment 539 
(Molander et al., 2014). An approach proposed by EFSA is a detailed analysis of different parameters of 540 
the study (e.g. statistical power; verification of measurement methods and data; control of experimental 541 
variables that could affect measurements; universality of the effects in validated test systems using 542 
relevant animal strains and appropriate routes of exposure, etc.) with detailed documentation of the 543 
process (EFSA, 2011).  544 
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2.6 Combined assessment of experimental data and in silico predictions 545 
2.6.1 Toxicological effect or mechanism assessment 546 
Reliable data, generally defined by Klimisch scores 1 or 2 reviewed by an expert (see Table 4), is ideally 547 
used for the toxicological effect or mechanism (shown in Figure 1) whenever available3. In the absence 548 
of adequate experimental data, results from one or more in silico models can be used to support 549 
assessment of the toxicological effect or mechanism. When multiple in silico model results, from 550 
potentially different methodologies, or QSAR models using different descriptors and/or training sets, are 551 
generated per toxicological effect or mechanism, the individual results need to be compiled to provide 552 
one overall assessment, as shown in Figure 1. This assessment may take into consideration information 553 
from any expert review of the in silico results, as certain results may need to be refuted. Similarly, when 554 
there are data assigned Klimisch 3 or 4 and/or there are in silico results, this information needs to be 555 
compiled into an overall assessment. Individual IST protocols will document such procedures. 556 
There are multiple approaches to compile results. A cautious approach is to use the most conservative 557 
data or prediction for this assessment. For example, when predicting the results of the bacterial reverse 558 
mutation test using two models, if either ŵodel’s prediĐtioŶ result is mutagenic then the overall 559 
assessment is mutagenic. Other options include a weight-of-evidence or consensus approach or 560 
selection of the prediction with the highest confidence (e.g., predictive probability score and relevance 561 
of analogous structures). Specific considerations per endpoint may be addressed in the individual IST 562 
protocols and may be dependent on the problem formulation.  563 
                                                 
3 As mentioned in Section 2.5, where high quality experimental data are available (as shown in Figure 1), it may not be 
necessary to run in silico models. However, generating in silico predictions for chemicals with known values is sometimes 
performed to verify experimental results because an unexpected positive or negative experimental result in a physical assay 
may be explained by the presence of an active impurity or to provide additional weight-of-evidence or for other reasons. 
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2.6.2 Reliability scores 564 
Reliability, in this context, is defined as the inherent quality of the experimental study (Klimisch, 1997) 565 
and/or in silico analysis. It is used to support any hazard assessment, in combination with other 566 
information. A reliability score (RS) is associated with the toxicological effect or mechanism assessment 567 
(as shown in Figure 1). As noted earlier, when data from the literature or other sources are considered, 568 
Klimisch scores can be used to assess the reliability of the results. However, the Klimisch framework was 569 
never intended to assess the reliability of in silico predictions.  It is also important to note that regardless 570 
of the approach taken, reliability assessments will contain subjective decisions. 571 
A number of general factors can affect the reliability of in silico results: 572 
 Multiple in silico results: Combining results from multiple complementary or independent in 573 
silico tools which use different methodologies or QSAR descriptors and/or training sets, has 574 
been shown to improve overall sensitivity, but it can lower specificity by increasing false positive 575 
rates (Myatt et al., 2016). In the case of quantitative predictions, such process are overly 576 
conservative estimates. Hence, consistency across several different models can increase the 577 
reliability of the results. 578 
 Expert review: A plausible and well-documented read-across (consistent with the RAAF or 579 
similar frameworks) may be acceptable as part of a REACH regulatory submission as an 580 
alternative to experimental data. A structured expert review is implicit in any read-across 581 
assessment (as discussed in Section 2.4.4). Similarly, an explicit expert review (following the 582 
elements described in Sections 2.4.2 and 2.4.3) of the in silico predictions can improve the 583 
reliability of the final results, especially for negative predictions. (Dobo et al., 2012)  584 
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To generate an overall reliability score for assessments based on experimental data and/or in silico 585 
predictions, the Klimisch score has been adapted (as shown in Figure 2) to include an assessment of in 586 
silico prediction results. 587 
Experimental data assigned a Klimisch score of 1 or 2 is assigned a score of RS1 and RS2, respectively, in 588 
this revised scheme. In silico results are not assigned a score of RS1 or RS2 since adequate experimental 589 
data is preferred over in silico predictions. Since in silico results may be used directly as part of certain 590 
regulatory submissions, whereas experimental data with a Klimisch score of 3 or 4 would not (or only as 591 
supporting data under REACH, for example), the next two categories (RS3 and RS4) represent, in part, in 592 
silico predictions. The following may be acceptable as part of a regulatory submission: (1) an adequately 593 
performed read-across prediction (EU 2006), or (2) an expert review of in silico and/or other 594 
experimental data (ICH M7, 2017(R1); EU 2006); they are assigned a reliability score of RS3. A score of 595 
RS4 would be assigned when two or more predictive models are available that are complementary, with 596 
concurring results (with no expert review), and no supporting literature data are available. Examples 597 
include those predictive models that use either substantially different QSAR descriptors and/or QSAR 598 
training sets or different in silico methodologies. If two or more in silico model results do not agree, then 599 
an expert review would be required to assess the results. This review might increase the confidence in 600 
the assessment, resulting in an increased reliability score of RS3. A single acceptable (as discussed in 601 
Section 2.3.2) in silico model result, without further expert review, is afforded the same reliability score 602 
of RS5 as an actual test result of lowest reliability (Klimisch 3 or 4). The in silico result is placed in the 603 
same category as low reliability data because such models inform decisions based on a series of 604 
compounds or trends However, this reliability score may be increased following expert review. This 605 
reliability score closely follows the ICH M7 guideline, where submissions corresponding to reliability 606 
scores RS1-RS4 would be accepted according to the guideline. In addition to this score, it may be helpful 607 
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to document any additional considerations that may be important to the overall assessment. Individual 608 
IST protocols may deviate from this scheme with appropriate justification. 609 
2.6.3 Worked examples 610 
Three examples from Amberg et al. (2016) illustrate how the framework described in this publication 611 
can be used for determining a toxicological effect or mechanism assessment and reliability score, based 612 
on experimental data and/or in silico predictions. Assessing reliability is an initial step in the overall 613 
assessment of hazard, where it will be combined with other information, including an evaluation of the 614 
relevance of the information, to support decision making. 615 
In the example in Figure 3, no experimental data were identified. Two in silico models were run; the 616 
statistical-based model prediction was negative and the expert rule-based alert prediction was negative. 617 
The initial score would be RS4 based on multiple concurring prediction results; however, an expert 618 
review was performed on the results from both methodologies and the negative result was confirmed 619 
with increased reliability. The review concluded there were no potentially reactive features in the 620 
chemical. This resulted in a negative overall assessment and a reliability score of RS3 (as a result of the 621 
expert review increasing the reliability).  622 
In the example in Figure 4, no experimental data were identified. Two in silico models were run; the 623 
statistical model prediction was positive and the expert alert prediction was positive. No expert review 624 
of the results was performed. The overall assessment was therefore positive and a reliability score of 625 
RS4 was assigned as a result of two concurring positive predictions using complementary in silico 626 
methodologies but without expert review.  627 
In the example in Figure 5, no experimental data were identified. Two in silico models were run; the 628 
statistical model prediction was positive and the expert alert prediction was negative. An expert review 629 
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was performed on the results from both methodologies, refuting the statistical model’s positive 630 
prediction. This review was based on an analysis of the test ĐheŵiĐal’s potential to react with DNA and 631 
the highlighted structural feature was determined to be irrelevant for the mechanism of interaction with 632 
DNA. This resulted in a negative overall assessment and a reliability score of RS3 (as a result of the 633 
expert review increasing the reliability).  634 
2.7 Hazard assessment framework 635 
2.7.1 Toxicological endpoints 636 
Figure 6 illustrates a general scheme for the prediction of a major toxicological endpoint. In this scheme, 637 
the specific toxicological effects or mechanisms are used to support the assessment of a series of 638 
toxicological endpoints. These toxicological endpoint assessments are, in turn, used in the overall 639 
assessment of the major toxicological endpoint. In Figure 6, effect/mechanism 1 is identified as being 640 
relevant to an assessment of a specific toxicological endpoint (Endpoint 1). For example, bacterial gene 641 
mutation (effect/mechanism 1) is relevant to the assessment of gene mutation (endpoint 1). Endpoint 1 642 
is, in turn, one of the endpoints that are relevant to the major toxicological endpoint (e.g., genetic 643 
toxicity). Other identified toxicological effects or mechanisms are associated with toxicological 644 
endpoints as shown in Figure 6. For example, the mammalian gene mutation (effect/mechanism 2) is 645 
also relevant to the assessment of gene mutations (endpoint 1) and clastogenicity (endpoint 2) is 646 
another endpoint to be used in the assessment of genetic toxicity (a major toxicological endpoint). 647 
Figure 6 also includes another example to illustrate how this scheme might be used to assess male 648 
reproductive toxicity. 649 
The hazard assessment framework scheme for each IST protocol will contain different numbers of 650 
toxicological endpoints as needed to support the assessment of each major toxicological endpoint in a 651 
complete and transparent manner.  652 
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It is noteworthy that only the toxicological endpoints required to support a particular problem 653 
formulation need to be assessed. For example, in certain applications only an assessment of gene 654 
mutation may be needed (i.e., it may not be necessary to compute clastogenicity or the genetic toxicity 655 
major toxicological endpoint). 656 
2.7.2 Relevance 657 
Relevance, in this context, is defined as the scientific predictivity of the each toxicological effect or 658 
mechanism for the purpose of assessing a specific toxicological endpoint. As shown in Figure 6, the 659 
assessment of toxicological endpoints may be based on the associated toxicological effects or 660 
mechanisms. To support a transparent overall analysis, the relevance of the toxicological 661 
effect/mechanism information in support of the assessment of the associated toxicological endpoint will 662 
be defined in the IST protocols. This relevance will be based on the collective experience of the 663 
consortium and available validation information.  664 
2.7.3 Toxicological endpoint assessment 665 
The assessment of each toxicological endpoint (as shown in Figure 6) is a function of all associated 666 
toxicological effects or mechanisms and, in some cases, other toxicological endpoints. For example, in 667 
Figure 6, bacterial gene mutation and mammalian gene mutation (toxicological effects or mechanisms) 668 
are associated with gene mutation, whereas gene mutation and clastogenicity (both toxicological 669 
endpoints) are associated with genetic toxicity. Rules or general principles for combining all associated 670 
results for each endpoint will be defined in the upcoming IST protocols. For example, a rule may state 671 
that if one of the associated effects/mechanisms is positive then the endpoint assessment is positive. 672 
These rules or principles will take into consideration how combinations of different toxicological 673 
effects/mechanisms are evaluated to generate an assessment for any toxicological endpoint which may 674 
include a sequence of steps and incorporate Boolean logic.  675 
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2.7.4 Toxicological endpoint confidence 676 
Confidence, in this context, is defined as a score that combines the reliability and relevance of the 677 
associated toxicological effects or mechanisms. This is an additional score associated with toxicological 678 
endpoints. The score may, in some cases, use other toxicological endpoint confidence scores (as shown 679 
in Figure 6). This score will also take into consideration the completeness of the information available; 680 
for example, the confidence score may be lowered when information on an effect or mechanism is 681 
missing. It will also include complementary effects or mechanisms that need to be considered. This 682 
score will be generated based on a series of general principles and/or rules defined in each IST protocol. 683 
Each protocol will outline the different confidence values to generate, such as high, medium or low. 684 
A confidence score is one of the most important items to generate. Different decision contexts tolerate 685 
a different level of confidence in the assessment result as exemplified in the following two scenarios.  686 
1) Scenario 1. The decision is to prioritize a large number of chemicals to screen as part of 687 
product development. In this scenario, selecting a small subset of compounds using in silico 688 
methods supports strategic resource utilization with the eventual goal of reducing overall 689 
costs.  690 
2) Scenario 2. A regulatory submission for a new cosmetic ingredient is being prepared based 691 
on results from in silico methods.  692 
Although in both scenarios, toxicological endpoint assessments generated at the highest level of 693 
confidence would be preferable, Scenario 1 could still make beneficial use of lower confidence 694 
predictions because the safety consequences of a false negative is lower than in Scenario 2. Therefore, a 695 
risk assessment which takes into account the acceptable tolerance for a wrong prediction can be used to 696 
evaluate the necessity for high confidence. 697 
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The assignment of the confidence score for each toxicological endpoint has to support the decision 698 
context(s), regulatory framework and the type of product being assessed. Minimum confidence scores 699 
for regulatory purposes may need to be set; however for other applications, the use of these scores may 700 
ďe ďased oŶ the iŶdiǀidual orgaŶizatioŶ’s risk tolerance or based on the context, a decision on the 701 
maximum permitted effort to be expended (since higher confidence score may be generated with 702 
additioŶal resourĐesͿ, or aŶ orgaŶizatioŶ’s iŶterŶal poliĐǇ for usiŶg the ĐoŶfideŶĐe sĐores for speĐifiĐ 703 
tasks. 704 
2.7.5 Expert review of toxicological endpoints 705 
In certain situations, an expert review of the toxicological endpoint assessment and/or confidence may 706 
be warranted, and specific points to consider as part of such an expert review will be detailed in the 707 
individual IST protocols. This review may take into consideration the context of the assessment, that is, 708 
the type of product being assessed and any potential regulatory framework. It may be helpful to 709 
document any additional considerations concerning the assessment and confidence to support an 710 
overall assessment. 711 
2.8 In silico toxicology protocol components 712 
Ongoing efforts are concentrated on the development of individual IST protocols for major endpoints 713 
including genetic toxicity, carcinogenicity, acute toxicity, repeated dose toxicity, reproductive toxicity, 714 
and developmental toxicity. Table 5 outlines proposed common components for these IST protocols. 715 
2.9 Reporting formats 716 
Standardized reporting of the results and expert review is good scientific practice and assures that when 717 
such information is communicated to regulatory authorities, it is complete, consistent and transparent; 718 
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this may avoid requests for additional information and maintain a consistent, expedient, and streamline 719 
regulatory review process. Table 6 outlines a proposed structure for the report format. 720 
The proposed report format is more comprehensive than existing data formats by including information 721 
on overall assessment and expert reviews. For example, the ͞Q“AR prediĐtioŶ reportiŶg forŵat͟ ;QPRF; 722 
JRC 2014) could be used to report the individual model results (as shown in Section D of Table 6), or 723 
͞Q“AR ŵodel reportiŶg forŵat͟ (QMRF) can be used to report the Q“AR ŵodel’s details (as shown in 724 
Section H of Table 6). 725 
The new proposed report format collects enough details on how the predictions were generated to 726 
enable another expert to repeat the process. It is also important that the reasoning and decisions of the 727 
expert review steps are transparently documented and can be retraced at any time, including the 728 
information used as their basis for conclusions. 729 
3. Summary and outlook 730 
IST is poised to play an increasingly significant role in the assessment of chemicals in a range of chemical 731 
exposure scenarios that have the potential to impact public health. Thus, this is an opportune time for 732 
the development of IST protocols. As expected, the quality and quantity of experimental data will vary 733 
as will the available in silico methods. For example, experimental data could be from a variety of 734 
sources, studies, protocols and laboratories using or not using GLP standards. Similarly, several in silico 735 
methods and approaches are available for assessment of toxicity. Thus, accepted selection criteria have 736 
to be defined for experimental data and in silico methods, for consistent and uniform use. The 737 
development of IST protocols will support the use and adoption of in silico methods in the same manner 738 
in which in vitro and in vivo test guidelines support the use and adoption of those assays.  739 
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Figure 7 summarizes the steps to perform an in silico assessment consistent with the framework defined 740 
in this publication. The key elements needed for the development of IST protocols are outlined in this 741 
publication, including: 1) how to select, assess and integrate in silico predictions alongside experimental 742 
data for defined toxicological effects or mechanisms, including a new methodology for establishing the 743 
reliability of this assessment, 2) a hazard assessment framework for systematic assessment of these 744 
toxicological effects or mechanisms to predict specific endpoints and assess the confidence in the 745 
results. Wherever possible, this is based on mechanistic knowledge on different biological levels of 746 
organization. (Bell et al., 2016; OECD 2016a; OECD 2016b) Overall, the IST protocols will contain 747 
information to ensure predictions are performed in a consistent, repeatable, transparent and ultimately 748 
accepted manner and will include a checklist (as defined in Section 2.4) to guide an expert review of the 749 
information. Each individual IST protocol will address how predictions will be performed in alignment 750 
with the framework discussed in this publication. These new protocols will provide specific guidance for 751 
each toxicological endpoint, including situations where no AOP or IATA is currently available. These 752 
protocols build on and fully incorporate wherever possible the considerable work previously reported, 753 
such as the OECD validation principles (see Sections 2.3.2), IATAs (see Sections 2.2), AOPs (see Sections 754 
2.2), read-across frameworks (see Sections 2.3.2, 2.6.2), the Klimisch score (see Sections 2.5, 2.6.1, 755 
2.6.2)  and the QMRF/QPRF (see Sections 2.3.2, 2.9). 756 
The IST protocols do not define how a risk assessment will be performed; they solely define the process 757 
which will lead to the prediction of the potential toxicity (hazard) of a chemical. Risk analysis depends on 758 
the exposure scenario, industry, regulatory framework and decision context based on the level of 759 
tolerated uncertainty and is performed in the hands of an expert. 760 
The process of developing IST protocols requires an understanding of the best practices and science 761 
across various organizations, different industries and regulatory authorities. To develop such protocols, 762 
In silico toxicology protocol (17 November 2017) Page 38 
 
an international consortium was established comprising regulators, government agencies, industry, 763 
academics, model developers, and consultants across many different sectors. This consortium initially 764 
developed the overall strategy outlined in this publication. Working subgroups will develop individual 765 
IST protocols for major endpoints including genetic toxicity, carcinogenicity, acute toxicity, reproductive 766 
toxicity, and developmental toxicity. As each IST protocol is established, it will be reviewed internally 767 
within each organization and published. This process will evolve over time, as computational technology 768 
progresses, as will the assays and other information relevant to assessing these major endpoints 769 
emerges. Hence, similar to other test guidelines, the IST protocols will need to be periodically reviewed 770 
and updated. The implementation of IST protocols will also require user-friendly tools for performing 771 
such analyses and reporting the results, education, as well as further collaboration with organizations to 772 
support global adoption. 773 
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Figure Legends 1079 
Figure 1: Overview of the IST protocol framework, showing how experimental data or in silico model(s) 1080 
for each defined toxicological effect/mechanism are assessed and used to support a hazard assessment. 1081 
(Note Effect/Mechanism N is used to illustrate that there can be any number of effects/mechanisms in 1082 
each protocol) 1083 
Figure 2: Reliability of toxicity assessments based computational models and experimental data 1084 
Figure 3: Determining the bacterial gene mutation assessment and reliability score for two concurring in 1085 
silico results with expert review 1086 
Figure 4: Determining the bacterial gene mutation assessment and reliability score for two concurring in 1087 
silico results with no expert review 1088 
Figure 5: Determining the bacterial gene mutation assessment and reliability score where there is no 1089 
experimental data available and conflicting in silico results 1090 
Figure 6: Hazard assessment framework 1091 
Figure 7: Summary of the IST protocol process 1092 
 1093 
  1094 
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Tables 1095 
 1096 
Table 1: Applications of in silico toxicology 1097 
In silico toxicology 
application 
Discussion 
1. Alternative to 
test data. 
The use of non-animal alternative methods including in silico approaches, may substitute for 
other types of tests in regulatory submissions in certain cases. Acceptable alternative methods 
for filling data gaps are outlined in Annex XI of the EuropeaŶ UŶioŶ’s REACH regulation (EU 
2006). In the United States, Frank R. Lautenberg Chemical Safety for the 21st Century Act revised 
the Toxic Substances Control Act (TSCA) to include predictive models and expert review as part 
of an overall assessment (TSCA 2016). The United States Food and Drug Administration (US FDA) 
Center for Devices and Radiological Health (CDRH) issued a guidance for industry and FDA staff. 
This guidance is on the use of International Standard ISO 10993-1 for biological evaluation of 
medical devices and indicates in the absence of experimentally derived carcinogenicity 
information, structure activity relationship modeling for these materials may be needed (CDRH 
2016). The FDA draft guidance on Electronic Nicotine Delivery Devices (ENDS) also discusses the 
use of computational toxicology models in the absence of toxicological data for potential 
toxicants created by the aerosolization process (PMTA/FDA 2016). When chemicals with limited 
toxicity data are required to be classified and labeled for shipping or other purposes, in silico 
toxicology provides an alternative method for quickly filling the data gaps in the toxicity/safety 
information, such as predictions of acute toxicity to support assignment to the Globally 
Harmonized System of Classification and Labelling category (Freidig et al., 2007; ECHA 2015). 
2. As part of the 
weight-of-
evidence in 
regulatory 
submissions. 
There are currently several regulatory frameworks where only specific laboratory tests for an 
endpoint of concern may be submitted (such as for drugs or food additives). However, in such 
cases, in silico predictions can be submitted alongside standard toxicological data to 
complement the assessment. This may include in silico assessments provided as supporting data 
or adjuncts to the primary in vivo or in vitro studies to give a mechanistic understanding of the 
observed results and/or allow a better definition of experimental needs. Additionally, in silico 
methods may be used to guide or prioritize in vitro testiŶg ;EU ϮϬϭϮͿ. The EuropeaŶ UŶioŶ’s 
Cosmetics Regulation (EU 2009a) prohibits the use of animal testing for products or ingredients 
and a complete marketing ban of such products tested as a whole or containing tested 
ingredients. This requires the use of alternative methods, such as IST, in the assessment of new 
ĐosŵetiĐs iŶgredieŶts. IŶ a reĐeŶt ŵeŵoraŶduŵ, the EuropeaŶ CoŵŵissioŶ’s “ĐieŶtifiĐ 
Committee for Consumer Safety (SCCS), which is responsible for the risk assessment of cosmetic 
ingredients, acknowledged the importance and limitations of in silico methods; the SCCS 
recommended that in silico methods be used either for internal decision making or as part of a 
weight-of-evidence (WOE) approach to estimate toxicity risks before embarking on any 
experimental testing (SCCS 2016). 
3. Mixtures 
assessment. 
Most exposures are not to a single chemical but rather to complex mixtures of chemicals that 
may be found in food, beverages, the environment, cigarette smoke, electronic nicotine delivery 
systems (ENDS) aerosols, botanical drugs or natural products. In certain situations, it may be 
possible to use in silico methods to assess individual components since today’s in silico analysis 
can only be performed on discrete identifiable chemicals. While preliminary analytical work is 
required to identify all chemicals in the mixture above appropriate Analytical Evaluation 
Thresholds (AET) (Ball and Norwood 2012), leveraging in silico approaches may avoid having to 
synthesize or purify each of the potentially large number of mixture components to perform 
standard toxicological tests (Mumtaz et al., 2010). Careful consideration is required for mixtures 
when there are multiple chemicals for interactions, such as synergistic or additive effects that 
may have the same, similar or different mechanisms of action (MOA). 
4. Assessment of 
impurities and 
degradation 
products. 
Chemicals, such as pharmaceuticals or plant protection products, may contain low levels of 
impurities produced during manufacturing and degradation. Many such substances, when 
present at levels above accepted thresholds, need to be assessed. In most cases, mutagenicity 
evaluation of the impurity under question is required as a first step of the risk assessment. 
(Harvey et al., 2017) The ICH M7 guideline provides specific recommendations for assessing drug 
impurities (ICH M7, 2017(R1)), including the use of two complementary computational 
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toxicology methodologies (i.e., statistical and expert based models) to predict bacterial 
mutagenicity. 
5. Residues of 
plant 
protection 
products. 
Residues of plant protection products may be evaluated as a part of residue definition for 
dietary risk assessment of plant protection products (EU 2009b). In this context, in silico 
methods provide a useful alternative approach. (EFSA 2016) 
6. Assessment of 
extractables 
and leachables. 
Medical devices, such as inhaled aerosols, food-contact substances, and consumer product 
packaging materials may pose a risk for human health due to release of potentially harmful 
chemicals that are used in the production of the components (Bossuyt et al., 2017). These 
include plasticizers, copolymers, vulcanization additives, etc. for which toxicological data is often 
lacking but where a risk assessment must be performed. A migration or leachables study 
supports the discovery, identification, and quantification of any leachables. An in silico 
toxicological assessment, in certain situations, can provide sufficient data for the risk 
assessment. 
7. Workers’ safety 
and 
occupational 
health. 
Chemicals used in the manufacture of a product are assessed for mutagenicity, carcinogenicity, 
skin and respiratory sensitization, irritation (skin, eye and respiratory), and reproductive and 
developmental toxicity and possibly acute toxicity. In silico assessments make it possible to 
estimate the potential toxicity of chemicals and adopt proper engineering controls and personal 
protective equipment usage to protect workers who could be exposed to these substances 
during production, transfer, storage, and delivery processes (EU 2006). In silico approaches have 
been utilized to assess these major toxicological endpoints in the occupational safety setting. In 
silico methods to predict respiratory sensitization potential of industrial chemicals have recently 
been reviewed by Seed and Agius (2017). 
8. Metabolite 
analysis. 
Metabolites can present an increased or decreased risk of local or systemic toxicity compared 
with the parent chemical (Mumtaz and Durkin, 1992). While reactive or toxic metabolites may 
be formed by an organism, their identification, separation as well as possible synthesis for 
testing purposes may be challenging. In silico methods provide a practical alternative approach 
to understanding the safety profiles of this potentially large number of chemicals as well as to 
support the prediction of metabolites. 
9. Ecotoxicology. Various chemicals are discharged into the environment that may cause harm. Furthermore, the 
parent compounds can be transformed by hydrolysis, redox-reactions, or photolysis into 
numerous additional chemicals. IST methods often provide the most practical approach to assess 
the potential effects on the environment and wildlife species of the many chemicals that are 
discharged. Prediction of physicochemical parameters supports assessment of potential 
environment exposure to the chemical (e.g., persistence and distribution). As an example, Chen 
at al., 2015 describes the use of in silico assessment of potentially hazardous contaminants 
present in water. 
10. Green 
chemistry and 
safer 
alternatives. 
In silico methods can play an important role when identifying alternative chemicals that may 
have a safer profile than existing chemicals (Rastogi et al., 2014). This includes, for example, 
alternatives for use in manufacturing processes, alternative packaging/delivery materials and the 
use of specific additives. In silico methods can provide insights about structural features 
responsible for the toxicity of different groups of chemicals and thereby allow for the rational 
design of intrinsically safer chemicals. 
11. Selection of 
product 
development 
candidates. 
In early product discovery or development, many thousands of compounds may be evaluated. In 
silico methods may provide a helpful approach to selecting candidates, since in silico methods 
are inexpensive, rapid to perform, and high throughput. In addition, in silico methods can 
suggest which molecular substructures (toxicophores) are responsible for the predicted toxic 
activity, thereby supporting the optimization of future compounds (Hillisch et al., 2015; Myatt et 
al., 2016). Later in the product development process, a smaller number of chemicals may be 
selected as candidates to take forward for further development; in normal situations, preference 
would be given to the candidate(s) with the most advantageous safety profile(s) (Myatt et al., 
2016). 
12. Emergency 
response 
situations. 
When one or more chemicals are unexpectedly released into the environment (e.g., the West 
Virginia chemical spill (NTP 2016)) or into a production process, it is important to quickly 
evaluate the potential effects on humans, wildlife, and the environment. In such emergency 
situations the toxicological profile of the released chemicals needs to be established as quickly as 
possible to support the proper emergency response and to protect emergency services staff and 
bystanders (Hochstein et al., 2008; Schilter, et al., 2014). In such a limited timeframe and in the 
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absence of previously generated data, in silico approaches may be a practical option for rapid 
hazard identification. 
13. Prioritizing 
testing of 
chemicals. 
In silico approaches can help prioritize in vitro and in vivo toxicology testing, based upon the 
ĐheŵiĐal’s eǆposure aŶd prediĐtioŶ of toǆiĐitǇ; theǇ are aŶ iŵportaŶt aspeĐt of the ǁork at 
several organizations such as the US EPA, National Toxicology Program, Environment and 
Climate Change Canada and ECHA (Schwetz 1995). In silico methods may be used to prioritize 
(based on potential toxicological liabilities) the order in which a series of toxicological studies will 
be performed (Myatt et al., 2016).  
14. Rationalization 
of in vivo or in 
vitro study 
results. 
As mentioned previously in the description of the in silico appliĐatioŶ titled ͞As part of the 
weight-of-evidence in regulatory studies”, results from quantitative structure-activity 
relationship (QSAR) models (toxicophore information, chemical fragments or physicochemical 
properties) may be used in conjunction with biological data to infer a mechanism of action 
(MOA), molecular initiating event (MIE), or mode of toxicity as part of an adverse outcome 
pathway (AOP) (Martin et al., 2015; Ellison et al., 2016). Information from in silico methods can 
also be used to tailor an in vivo study, e.g., by inclusion of additional endpoints. When existing 
experimental data on a compound are equivocal or when not all relevant safety information are 
available or accessible, in silico data may be used as additional information as part of the weight-
of-evidence approach in reaching a more informed decision (Kruhlak et al., 2012). 
 1098 
 1099 
  1100 
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Table 2: Checklist of elements to consider as part of an expert review of a QSAR model result  1101 
Expert review elements Considerations 
A. Inspection of model output  A review of the appliĐaďilitǇ doŵaiŶ iŶforŵatioŶ proǀided ďǇ the ŵodel’s 
software might increase or decrease reliability in the prediction.  The results of the QSAR model might include a score (e.g., a probability of 
a positive outcome). The prediction reliability may be increased where a 
score indicating a high likelihood can be justified through an expert review 
of the available information. 
B. Analysis of structural descriptors 
and corresponding training set data 
(see Note A) 
 As part of the process of building a QSAR model, structural descriptors are 
selected (often automatically) when there is a statistical association to the 
(toxicological) data to be predicted; however, the selected descriptors 
might not be biologically meaningful for the predicted toxicological 
effect/mechanism, as discussed in Powley (2015). This assessment may be 
supported by inspecting the training set examples that match the 
descriptors wherever possible. An expert review may determine the result 
is incorrect if other structural moieties in the training set examples are 
more likely responsible for the biological activity, (i.e., the descriptors 
identified were coincidental and in fact irrelevant) (Amberg et al., 2016).   Another scenario is when the structural descriptors map to experimental 
data that is incorrect and attributable to known problems with an assay. 
Again, these features may be discounted if they are not relevant to the 
toxicological effect or mechanism and this may lead to a reversal of the 
overall assessment. For example, chemicals containing acid halides may 
give false positive results due to possible interaction with the solvent 
DMSO in the Ames assay (Amberg et al., 2015).  Descriptors identified as significant by the model that are also present in 
the query compound may be associated with a biological mechanism. An 
expert review may evaluate whether the mechanism is plausible for the 
query compound, including potential metabolism consideration. For 
example, does the highlighted feature represent a known reactive group 
or a known toxicophore? This analysis may lead to an increase in 
prediction reliability.   IŶ soŵe sǇsteŵs, it is possiďle to iŶspeĐt the traiŶiŶg set’s eǆperiŵeŶtal 
data and references for those examples that are primarily used in the 
prediction. An assessment of these full studies for these examples (as 
discussed in Section 2.5) could be used to justify an increase in the 
reliability of the prediction result.  The structural diversity of the underlying chemicals for each significant 
descriptor may be reviewed as part of an expert review. Structural 
features that map to a large number of structurally diverse compounds 
would provide additional evidence that the toxicological effects or 
mechanisms associated with the descriptor could be extrapolated across 
different chemical classes (increasing reliability in the prediction), 
whereas a structural feature whose underlying data constitutes a 
congeneric series might not, especially if the query compound is 
structurally distant (decreasing reliability in the prediction). 
C. Analysis of physicochemical 
descriptors used by model (see 
 Is there any supporting information from the literature or elsewhere to 
support any correlation between the physicochemical properties 
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Note B) identified as significant by the model and the toxicological 
effect/mechanism?  An evaluation of the quality of the experimental data of the training set 
chemicals used for building of the model (e.g., if a guideline study was 
used to generate these data) may increase the reliability of the prediction 
result. 
D. Assessment of other information  An evaluation of the performance of the model for structurally similar 
substances with known activity (selected by the user or provided by the 
system) might affect the evaluation of the reliability of the prediction. 
(Note A: items to consider when the QSAR model includes structure-based descriptions; Note B: items to consider when the 1102 
QSAR model includes physicochemical descriptors) 1103 
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Table 3: Checklist of elements to consider as part of an expert review of results from expert rule-1105 
based 1106 
Expert 4review elements Considerations 
A. Alert score or qualitative output  The results from the alert system might include information related to the 
likelihood of a positive outcome (e.g., precision of the alert). The reliability 
of the prediction may be increased when such a score can be justified 
through an expert review of the information provided. 
B. Justification of negative prediction  Additional considerations may be important where no alerts are identified 
in the test chemical. Such analysis may focus on similar analogs as well as 
other chemicals containing the different structural elements of the test 
chemical to verify there is no potential toxicity attributable to these 
fragments, such as additional reactive features. Such analysis may be used 
to evaluate the reliability of the negative prediction.   If a negative prediction has a structure of concern, a further inspection of 
the rules may determine why the compound was not included to 
elucidate the underlying cause for firing no alert. Is the prediction really 
negative, equivocal, or not in of the applicability domain of the model?.   
C. Reliability of the mechanism of 
toxicity 
 Although the presence of a structural alert increases the potential of the 
chemical to exert a toxicological effect or mechanism, this effect may 
depend on other features of the molecule. If a mechanism of toxicity is 
proposed for the structural alert, then an expert may assess the 
plausibility of the mechanism for the query compound. For example, the 
presence of other substituents in the molecule may impact the activity, 
potentially deactivating the alerting structure. This may include 
metabolism considerations. 
D. Inspection of chemicals and 
experimental data matching the 
alert 
 The reliability of the prediction can be assessed by the quality of the 
experimental data of the reference set substances used to make the 
prediction (e.g., if a guideline study to generate these data).  The structural diversity of the matching chemical may also be considered. 
For example, alerts that match diverse structures may increase the 
reliability over alerts where the matching chemicals are from a tight 
congeneric series. This is especially true when the reference set examples 
are structurally dissimilar from the query chemical.  Review of the scientific literature to support the alert to understand the 
strengths and limitations of the experimental data supporting it. 
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Table 4: Summary of Klimisch scores for data reliability (adapted from Klimisch et al., 1997) (Note 1108 
͞ƌestƌictioŶ͟, as paƌt of scoƌes ϭ aŶd Ϯ, iŵplies ƌestƌicted Ƌuality) 1109 
Score Description Summary 
1 Reliable without restriction  Well documented and accepted study or data from the literature  Performed according to valid and/or accepted test guidelines (e.g., 
OECD)  Preferably performed according to good laboratory practices (GLP) 
2 Reliable with restriction  Well documented and sufficient   Primarily not performed according to GLP  Partially complies with test guideline 
3 Not reliable  Inferences between the measuring system and test substance  Test system not relevant to exposure  Method not acceptable for the endpoint  Not sufficiently documented for an expert review 
4 Not assignable  Lack of experimental details  Referenced from short abstract or secondary literature 
 1110 
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Table 5: Common components of an IST protocol (IATA = Integrated Approaches to Testing and 1112 
Assessment; AOP = Adverse Outcome Pathways) 1113 
Introduction 
 
 Describe the major toxicological endpoint being assessed  Outline the general hazard assessment framework, including how a series of 
toxicological effects or mechanisms are related to one or more endpoints   Provide citations to any applicable AOPs or IATAs used 
In silico methodologies and 
models 
 
 Identify toxicological effects or mechanisms that might realistically be predicted  Define what in silico methodologies are appropriate to use  Specify additional considerations as to what constitutes an acceptable model  Discuss issues to be considered as part of any read-across analysis 
Experimental data 
 
 Define specific study types and result(s) relevant to each toxicological effect or 
mechanism  Define and justify the relevance of the information to the assessment of the 
toxicological endpoint (defined in the hazard assessment framework)  Define specific factors to consider when assessing the results and documenting the 
reliability of any available data or reference specific test guideline(s)  Identify sources of data that may be considered 
Toxicological effects or 
mechanisms assessment and 
reliability scores 
 Describe how each toxicological effect or mechanism assessment may be generated 
from available experimental data and/or in silico prediction(s)  Define additional items to consider as part of an expert review  Discuss any endpoint specific issues to consider as part of the reliability score  
Toxicological endpoint 
assessment and confidence 
 Describe the toxicological endpoints that will be used as part of the hazard assessment 
framework  Describe the rules or principles for determining each endpoint assessment, based on 
the associated effect/mechanisms or other endpoints  Define the rules or principles for determining each toxicological endpoint confidence, 
based on the relevance and reliability (from associated effects/mechanisms) or 
confidence (from associated endpoints)  Identify points to consider as part of any expert review 
Reporting  Define a format for a report of the results, expert review and conclusions 
Other considerations  Case studies 
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Table 6: Elements of an in silico toxicology report (QMRF = QSAR Model Reporting Format) 1115 
Section Content 
Title page - Title (including information on the decision context) 
- Who generated the report and from which organization 
- Who performed the in silico analysis and/or expert review, including their organization 
- Date when this analysis was performed 
- Who the analysis was conducted for 
Executive summary - Provide a summary of the study 
- Describe the toxicity or properties being predicted 
- Include a table or summary showing the following: 
o The chemical(s) analyzed  
o Summary of in silico results, reviewed experimental data and overall 
assessment for each toxicological effect or mechanism 
o Summary of toxicological endpoint assessment and confidence 
o Summary of supporting information 
Purpose - Specification of the problem formulation 
Materials and methods - QSAR model(s), expert alerts, and other models used with version number(s) and any 
parameters set as part of the prediction (e.g., QMRF format) 
- Databases searched with version number(s) 
- Tools used as part of any read-across with version number(s) 
Results of Analysis - Details of the results and expert review of the in silico models and any experimental 
data, including results of the applicability domain analysis 
- Report of any read-across analysis, including source analogs and read-across 
justifications 
Conclusion - Summarize the overall analysis including experimental data, in silico methods and expert 
review  
- Final prediction that is based on expert judgment 
References - Complete bibliographic information or links to this information, including test guidelines 
referred to in the experimental data, etc. 
Appendices (optional) - Full (or summary) study reports used or links to the report, detailed (or summary) in 
silico reports, reports on the models used (e.g., QMRF reports) 
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Figures 1118 
 1119 
Figure 1: Overview of the IST protocol framework, showing how experimental data or in silico 1120 
model(s) for each defined toxicological effect/mechanism are assessed and used to support a hazard 1121 
assessment. (Note Effect/Mechanism N is used to illustrate that there can be any number of 1122 
effects/mechanisms in each protocol) 1123 
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Figure 2: Reliability of toxicity assessments based on computational models and experimental data 1125 
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Figure 3:  etermining the bacterial gene mutation assessment and reliability score for two concurring in 1127 
silico results with expert review 1128 
 1129 
 1130 
 1131 
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Figure 4: Determining the bacterial gene mutation assessment and reliability score for two concurring in 1133 
silico results with no expert review  1134 
 1135 
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Figure 5: Determining the bacterial gene mutation assessment and reliability score where there is no 1137 
experimental data available and conflicting in silico results 1138 
 1139 
  1140 
In silico toxicology protocol (17 November 2017) Page 69 
 
Figure 6: Hazard assessment framework 1141 
 1142 
  1143 
In silico toxicology protocol (17 November 2017) Page 70 
 
Figure 7: Summary of the IST protocol process 1144 
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